TScan (TCRX) - Cumulative Company Assets

Corporate emblem and logo of TScan Therapeutics (TCRX)

TScan Therapeutics (TCRX) aims to expand its ImmunoBank system for the production of personalized tumor-targeted therapies. The company's revenue is based on grants and collaborations with pharmaceutical behemoths to create modified T-cells. This price action reflects total assets at 235.00. Pricing power is currently absent due to the trial stage, however, commercial success will provide the company with significant market leverage.

TCRX: TScan Therapeutics Aggregate Company Assets 07/04/2022 - 10/28/2026

Analytical breakdowns for tscan.com (TCRX)

- price and consensus price forecast:
Share Price TScan Therapeutics, Inc.|TCRX - Analyst Consensus Forecast
- market capitalization data:
Market Valuation TCRX|TCRX - Enterprise Value
- book capitalization data:
Book Value per Share TScan Therapeutics|TCRX - Company Book Value|Capitalization to Book Value Ratio tscan.com|TCRX - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio TScan Therapeutics|TCRX - Long-Term Debt to Capital|Current Liabilities to Capital TScan Therapeutics, Inc.|TCRX - Company Debts|Debt to Net Assets Ratio TCRX|TCRX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings TScan Therapeutics
Analysis of all company metrics:TCRX, TScan
Manufactured product of TScan Therapeutics

Total assets determine the aggregate volume of resources and liabilities, calculated reverse-engineered through profitability to assess the business's actual material base. Analyzing the property and resource calculations for TScan Therapeutics (TCRX) reveals that the absence of commercial products makes the company dependent on external financing, turning assets into a tool for sustaining clinical development until the point of reaching self-sufficiency.

Competitors of TScan Therapeutics (TCRX)

beigene.com (ONC) - Total Business Assets|Company Total Assets HALO|Cumulative Company Assets Revolution Medicines Inc|Company Total Assets AAPG|Company Total Assets CGON (CG Oncology Therapeutics)|URGN - Aggregate Company Assets|Total Business Assets bicara.com BCAX|PSNL: Company Total Assets|ERAS - Cumulative Company Assets|Company Total Assets DCTH|YMAB (Y-mAbs Corp) - Company Assets|AURA - Aggregate Company Assets|Aggregate Asset Value Candel (CADL)|Accuray (ARAY) - Cumulative Company Assets|Aggregate Asset Value sellaslifesciences.com (SLS)|Actuate Therapeutics, Inc - Company Total Assets|CTOR - Cumulative Company Assets|TuHURA - Cumulative Company Assets|TARA: Company Total Assets|Aggregate Company Assets Fate Therapeutics FATE|Aadi Bioscience (WHWK) - Aggregate Asset Value|Company Total Assets CSBR (Champions Oncology Inc)|Company Assets XBiotech USA (XBIT)|Cumulative Company Assets CEL-SCI Corporation|Aggregate Business Assets OSTX (ostherapies.com)|Aggregate Company Assets RADX|Company Total Asset Base Artiva Biotherapeutics Inc. ARTV|ANL: Company Total Assets|VERU - Cumulative Company Assets|TPST: Company Total Assets|XLO (Xilio Therapeutics) - Company Total Assets|Aggregate Company Assets Renovaro Biosciences (RENB)|Total Business Assets Mural Bio (MURA)|Kairos Pharma Ltd (KAPA) - Cumulative Company Assets|Aggregate Asset Value onkuretherapeutics.com OKUR|Cumulative Company Assets CytoMed Therapeutics Limited (GDTC)|Aggregate Business Assets Curis Inc. CRIS|Company Total Assets Apollomics Corp (APLM)|THAR - Aggregate Asset Value|Company Total Assets ADVB|GNPX (Genprex Inc) - Company Assets|CLDI - Aggregate Company Assets|Aggregate Asset Value sunshinebiopharma.com|Company Total Assets XBIO|Company Total Assets SLRX (Salarius Pharmaceuticals Inc)|Purple Biotech Corp (PPBT) - Aggregate Company Assets|Total Asset Value of Company American Oncology Network Inc AONC|BGNE (BeiGene, Ltd.) - Company Total Assets|checkpointtx.com (CKPT) - Company Assets|ELEV: Cumulative Company Assets|Company Total Assets iCAD|Ikena Oncology Inc. (IKNA) - Cumulative Company Assets|Aggregate Business Assets Notable Labs Corp|VIRX (Viracta Therapeutics) - Company Total Assets|Company Total Asset Base morphosys.com (MOR)|NAYA Biosciences Inc. - Company Total Assets|Ascentage Pharma Group International - Cumulative Company Assets